Aimmune Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aimmune Therapeutics's estimated annual revenue is currently $30.7M per year.
- Aimmune Therapeutics received $170.0M in venture funding in January 2019.
- Aimmune Therapeutics's estimated revenue per employee is $137,009
- Aimmune Therapeutics's total funding is $540M.
Employee Data
- Aimmune Therapeutics has 224 Employees.
- Aimmune Therapeutics grew their employee count by -40% last year.
Aimmune Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Aimmune Therapeutics?
Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to food allergens less dangerous. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy. Aimmune is located in Brisbane, California - the heart of San Francisco's biotechnology hub - with additional offices in the Kings Cross area of London and in Raleigh, North Carolina.
keywords:Biotechnology,Food & Beverages,Healthcare,Pharmaceuticals
$540M
Total Funding
224
Number of Employees
$30.7M
Revenue (est)
-40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aimmune Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Clinical Trial Manager | Reveal Email/Phone |
2 | Senior Director, Risk Management and Epidemiology | Reveal Email/Phone |
3 | Sr. BA | Reveal Email/Phone |
4 | LMS System Administrator, GxP | Reveal Email/Phone |
5 | Sr. Process Engineer | Reveal Email/Phone |
6 | Associate Director, Regulatory Advertising & Promotion | Reveal Email/Phone |
7 | Director, Midwest Region | Reveal Email/Phone |
8 | Business Systems Analyst | Reveal Email/Phone |
9 | SVP Strategy, Marketing and Innovation | Reveal Email/Phone |
10 | Assistant General Counsel | Reveal Email/Phone |
Aimmune Therapeutics News
... Ltd., OncoVista Innovative Therapies, Genadyne, Cork Medical, ... and key Food Allergy companies such as Aimmune Therapeutics, Inc.,...
13, will be a pivotal moment for Aimmune Therapeutics (AIMT 5), the biopharma company that developed the new treatment, called AR101.
Operator. Good afternoon, ladies and gentlemen, and welcome to the Aimmune Therapeutics, Second Quarter 2019 Earnings Conference Call.
BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food ...
BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy), an approach to treating life-threatening food allergies, today announced that Nestlé Health Science will make a $145.0 mill ...
Other Companies in Brisbane
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $41M | 226 | N/A | N/A |
#2 | $45.3M | 229 | N/A | N/A |
#3 | $52.9M | 229 | -10% | N/A |
#4 | $41.2M | 230 | 4% | N/A |
#5 | $62.3M | 231 | 6% | N/A |
Aimmune Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-11-07 | $145.0M | Nestlé Health Scienc | Nestlé Health Science | Article |
| 2018-02-21 | $177.5M | Undisclosed | Article | |
| 2018-11-29 | $98.0M | Undisclosed | Nestlé Health Science | Article |
| 2019-01-07 | $170.0M | Undisclosed | KKR | Article |